{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:06:59Z","timestamp":1790795219038,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Aims\/Introduction<\/jats:title><jats:p>We conducted a 5 year post\u2010trial monitoring study of our previous randomized 24 week, open\u2010label, active\u2010controlled trial that showed beneficial effects of ipragliflozin on metabolic dysfunction\u2010associated steatotic liver disease (MASLD), identical to those of pioglitazone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>In our previous trial, 66 patients with MASLD and type 2 diabetes were randomly assigned to receive either ipragliflozin (<jats:italic>n<\/jats:italic>\u2009=\u200932) or pioglitazone (<jats:italic>n<\/jats:italic>\u2009=\u200934). Upon its conclusion, 61 patients were monitored for 5\u2009years for outcome measures of MASLD, glycemic, and metabolic parameters. Differences between the two groups were analyzed at baseline, 24\u2009weeks, and 5\u2009years; changes in outcome measures from baseline were also evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At 5\u2009years, the mean liver\u2010to\u2010spleen attenuation ratio increased by 0.20 (from 0.78\u2009\u00b1\u20090.24 to 0.98\u2009\u00b1\u20090.20) in the ipragliflozin group and by 0.26 (from 0.76\u2009\u00b1\u20090.26 to 1.02\u2009\u00b1\u20090.20) in the pioglitazone group (<jats:italic>P<\/jats:italic>\u2009=\u20090.363). Similarly, ipragliflozin and pioglitazone significantly improved serum aminotransferase, HbA1c, and fasting plasma glucose levels over 5\u2009years. In the ipragliflozin group, significant reductions in body weight and visceral fat area observed at 24\u2009weeks were sustained throughout the 5\u2009years (\u22124.0%, <jats:italic>P<\/jats:italic>\u2009=\u20090.0075 and \u22127.6%, <jats:italic>P<\/jats:italic>\u2009=\u20090.045, respectively). Moreover, ipragliflozin significantly reduced the values of fibrosis markers (serum ferritin and FIB\u20104 index), was well tolerated, and had a higher continuation rate for 5\u2009years compared with pioglitazone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ipragliflozin and pioglitazone improved MASLD and glycemic parameters over 5\u2009years. In the ipragliflozin group, significant reductions in body weight and visceral fat mass persisted for 5\u2009years.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdi.14246","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T11:33:44Z","timestamp":1716377624000},"page":"1220-1230","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Long\u2010term effects of ipragliflozin and pioglitazone on metabolic dysfunction\u2010associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow\u2010up of a randomized, 24 week, active\u2010controlled trial"],"prefix":"10.1111","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-2375","authenticated-orcid":false,"given":"Daisuke","family":"Ito","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes Saitama Medical University  Saitama Japan"},{"name":"Department of Internal Medicine Ogawa Red Cross Hospital  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Ogawa Red Cross Hospital  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Haisa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Saitama Medical University  Saitama Japan"},{"name":"Department of Internal Medicine Ogawa Red Cross Hospital  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Saitama Medical University  Saitama Japan"},{"name":"Department of Internal Medicine Ogawa Red Cross Hospital  Saitama Japan"},{"name":"Satsuki Medical Clinic  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Saitama Medical University  Saitama Japan"},{"name":"Department of Internal Medicine Ogawa Red Cross Hospital  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigo","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Saitama Medical University  Saitama Japan"},{"name":"Department of Internal Medicine Ogawa Red Cross Hospital  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sumita","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Saitama Medical University  Saitama Japan"},{"name":"Department of Internal Medicine Ogawa Red Cross Hospital  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morifumi","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Satsuki Medical Clinic  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6012-0915","authenticated-orcid":false,"given":"Yoshihito","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Saitama Medical University  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Inukai","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology Higashiyamato Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3954-4983","authenticated-orcid":false,"given":"Akira","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Saitama Medical University  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029349"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24483"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.021"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0912063"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2010.518623"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2012.10.008"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164114561992"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00007"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.01.007"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2875w"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13279"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-016-0169-x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0518"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25539"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21496"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.05.033"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-010-0305-6"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13520"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1696"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2049"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01796-x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060326"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2019.12.007"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.14246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T20:30:22Z","timestamp":1744230622000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.14246"}},"subtitle":["Effect of ipragliflozin in MASLD"],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/jdi.14246"],"URL":"https:\/\/doi.org\/10.1111\/jdi.14246","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"2024-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}